In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Outlook 2022

Annual industry ranking and forecast

Voluntary Limits On Antibacterial Discharges Increase As Fear Of Resistance Grows

Executive Summary

Pharmaceutical companies are ratcheting up voluntary efforts to control discharges of antimicrobials from their plants and those of their active pharmaceutical ingredient suppliers so they won’t contribute to antimicrobial resistance. But will it be enough to fend off regulation in countries like India?

You may also be interested in...



FDA Email Alert: Next Day’s Manufacturing Volume Reporting Due Date Still Voluntary

Objections to 15 February reporting date established in draft guidance spurred rare last-minute notice assuring industry that it was a non-binding recommendation, not a requirement. Action reflects confusion that can arise in interpreting policy guidance.

Pharma Supply Chain Disruptions Increased Another 74% in 2021, Resilinc Says

The COVID-19 pandemic has both caused problems such as reduced preventive maintenance and exacerbated other issues, such as slowing recovery from extreme weather events, according to Resilinc CEO.

GAO Advises US FDA On Inspection Pilot Plans; Notes Increased Oversight Of OAI Downgrades

As omicron COVID-19 variant recedes, GAO shares thoughts on FDA’s plans for unannounced foreign inspections and translation services pilots. The report also details agency efforts to fill vacant foreign inspection positions.

Topics

UsernamePublicRestriction

Register

IV124949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel